Collaboration Revenue was Nurix Therapeutics’s largest product and service line in fiscal 2025, bringing in $53.98M of $83.98M (64%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Collaboration Revenue | $38.63M | $56.99M | $54.55M | $53.98M |
| License Revenue | — | $20.00M | — | $30.00M |
| Total | $38.63M | $76.99M | $54.55M | $83.98M |
Nurix Therapeutics brought in $83.98M from its two product and service lines in fiscal 2025, the year ended November 30, 2025. Nurix Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $54.55M. Collaboration Revenue was the largest at $53.98M (64.3%), ahead of License Revenue at $30.00M (35.7%).
Nurix Therapeutics began breaking out License Revenue in fiscal 2023, when it brought in $20.00M.
Gilead Agreement was Nurix Therapeutics’s largest revenue line in fiscal 2022, bringing in $23.70M of $38.70M (61%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 |
|---|---|
| Gilead Agreement | $23.70M |
| Sanofi Agreement | $15.00M |
| Total | $38.70M |
Nurix Therapeutics brought in $38.70M from its two revenue lines in fiscal 2022, the year ended November 30, 2022. Gilead Agreement was the largest at $23.70M (61.2%), ahead of Sanofi Agreement at $15.00M (38.8%).
Nurix Therapeutics (NRIX) reports its revenue by product and service and by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Collaboration Revenue was its largest product and service line, bringing in $53.98M (64.3% of the total), followed by License Revenue at $30.00M (35.7%).
Collaboration Revenue was Nurix Therapeutics' largest product and service line in fiscal 2025, bringing in $53.98M, or 64.3% of the $83.98M total across its two product and service lines.
Gilead Agreement was Nurix Therapeutics' largest revenue line in fiscal 2022, bringing in $23.70M, or 61.2% of the $38.70M total across its two revenue lines.
Every figure comes from Nurix Therapeutics' annual financial filings, as reported. Each line keeps the name Nurix Therapeutics gives it, and years follow its fiscal calendar.
Nurix Therapeutics' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.